Sort   by:  
 Page size 
UnknownA Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.
Not available
S-EPMC9135383 | biostudies-literature
UnknownCan We Lower the Burden of Antimicrobial Resistance (AMR) in Heavily Immunocompromised Patients? A Narrative Review and Call to Action.
Not available
S-EPMC12425879 | biostudies-literature
UnknownEfficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study.
Not available
S-EPMC10600076 | biostudies-literature
UnknownUsing peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.
Not available
S-EPMC10583024 | biostudies-literature
UnknownClinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Not available
S-EPMC7426107 | biostudies-literature
Sort   by:  
 Page size